No Data
Arvinas Announces Late-Breaking Oral Presentation of Phase 3 VERITAC-2 Trial Results for Vepdegestrant at ASCO 2025
Express News | Arvinas Announces Results From the Veritac-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (Asco) Annual Meeting
Arvinas Announces Results From the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research (AACR) Annual Meeting
Goldman Sachs Maintains Arvinas(ARVN.US) With Hold Rating, Cuts Target Price to $12
Possible Signal As Arvinas Insiders Sell US$850k In Stock